"treatment_name","treatment_type","treatment_amount","treatment_time","treatment_case","treatment_notes"
"CHEMO_DETAILS","GYN_DIAGNOSIS_CHEMO_INTENT_DESCRIPTION","STEROIDS_GT_10MG_DAILY","X2YR_ALKYLATING_AGENT","CHEMO_CONCURRENT_REASON_NOT_GIVEN","AGE_AT_CHEMOTHERAPY_START"
"CRT_CHEMOAGENT","CHEMO_DETAILS","BRACHYTHERAPY_TOTAL_DOSE_POINT_A","AGE_AT_CHEMOTHERAPY_START","CHEMO_CONCURRENT_REASON_NOT_OTHER","AGE_AT_CHEMOTHERAPY_STOP"
"X2YR_CAPECITABINE","ADJUVANT_CT","NUM_LINES_NTRK","AGE_AT_CHEMOTHERAPY_STOP","GYN_DIAGNOSIS_CHEMO_INTENT_DESCRIPTION","BRACHYTHERAPY_TOTAL_DOSE_POINT_A"
"CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED","ABLATION_EMBOLIZATION_TX_ADJUVANT","TX_ABRAXANE","STEROIDS_GT_10MG_DAILY","ADJUVANT_CT","PROTOCOL"
"STEROIDS_GT_10MG_DAILY","X2YR_ALKYLATING_AGENT","NEOADJ_CHEMOCYCLES","CRDB_TREATMENT_END_DAYS","ABLATION_EMBOLIZATION_TX_ADJUVANT","MARGINS_INVOLVED_HYSTERECTOMY"
"BRACHYTHERAPY_TOTAL_DOSE_POINT_A","CRT_CHEMOAGENT","ADJUVANT_CYCLES_NUM","X2YR_FULVESTRANT","IPCHEMO_FIRST_CRS","TX_SETTING"
"IO_DRUG","PD1_INHIBITOR_CONCURRENTLY_WITH_BCNU/CCNU","TOTAL_CYCLES_NUM_NEOADJUVANT_ADJUVANT","X2YR_VEGF_INHIBITOR","SALVAGE_CHEMO","NONINVASIVE_BLADDER_CA_TX_TYPE"
"X2YR_FULVESTRANT","IPCHEMO_FIRST_CRS","AGENT","SURGERY_DATE_RELATIVE_TO_DX_MONTHS","CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED","DX_TYPE"
"SECOND_LINE_TC_OR_SURGERY","SALVAGE_CHEMO","ALPELISIB_DOSE","PROTOCOL","IFN_TX_90_DAYS_PRIOR_TO_RESECTION","NEOADJUVANT_TREATMENT_DETAILS"
"PROTOCOL","AGE_AT_CHEMOTHERAPY_START","TX_BORTEZOMIB","AGE_AT_RADIATION_START","ANY_LINE_NTRK","CHEMO_REGIMEN_CATEGORY"
"X2YR_TAMOXIFEN","AGE_AT_CHEMOTHERAPY_STOP","TX_CABOZANTINIB (XL-148)","AGE_AT_RADIATION_STOP","IO_LINE","PRD_CHEMOTHERAPY"
"IO_THERAPY","CHEMOTHERAPY_PRIOR_SAMPLE_ACQUIRED","CHEMO_OTHER_CYCLES","YEAR_OF_SURGERY","RECEIVED_IO_AFTER_1ST_LINE","CHEMOTHERAPY_TYPE"
"NONINVASIVE_BLADDER_CA_TX_TYPE","POAR_COMBINED_CTLA_PD1","CHEMO_CYCLES","WEEKS_ON_STUDY","SECOND_LINE_TC_OR_SURGERY","REASON_FOR_TX_DISCONTINUATION"
"X2YR_ANTHRACYCLINE","IO_REGIMEN_MONOTHERAPY_VS_COMBINATION","CHEMO_CONCURRENT_DOSE","X2YR_ANTHRACYCLINE","CALC_TREATMENT_NAIVE","DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)"
"X2YR_ANTIHER2","STEROIDS_GT_10MG_DAILY","CHEMO_CONCURRENT_FRACTIONS_TOTAL","X2YR_ANTIHER2","PREVIOUS_MAPKI","FORMULATION"
"X2YR_CDK46","IFN_TX_90_DAYS_PRIOR_TO_RESECTION","NUM_LINES_CHEMO","X2YR_CDK46","CRDB_PRIOR_RX","PRD_HORMONE_THERAPY"
"X2YR_TAXANE","BRACHYTHERAPY_TOTAL_DOSE_POINT_A","ALKYLATING_CHEMOTHERAPY","X2YR_TAXANE","X2YR_TAMOXIFEN","HISTORY_MENOPAUSAL_HORMONE_THERAPY"
"X2YR_AIS","IO_DRUG","PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY","X2YR_AIS","NGS_PRIOR_THERAPY","IMMUNOSUPPRESSION"
"TX_ABRAXANE","ADC+IMMUNOTHERAPY","TX_CISPLATIN","DRUG_LAST_ADMIN","TREATMENT_ARM","INDUCTION"
"FOLIC_ACID_TX","X2YR_VEGF_INHIBITOR","NUMBER_OF_CYCLES_PLATINUM","ADMINISTRATION_OF_DRUG_WEEKS","TUMOR_TREATED","DETAILS_FIRST_LINE_COMMENTS"
"NEOADJ_CHEMOAGENT","ANY_LINE_NTRK","TMZ_CYCLES","ALPELISIB_SCHEDULING","TERT_IO_TX","PREVIOUS_TREATMENT"
"ADJUVANT_CHEMO","IO_LINE","CYCLES_COMPLETED","CHEMO_CONCURRENT_COURSE","POST_MAPK_TX","PRD_OTHER_CANCER_RADIATION"
"NEOADJ_CHEMO","RECEIVED_IO_AFTER_1ST_LINE","NUMBER_OF_CYCLES_PEMBROLIZUMAB","CHEMO_OTHER_CYCLES","PRIOR_MAPK_TX","PRD_RADIATION"
"NEOADJUVANT_CHEMO","SECOND_LINE_TC_OR_SURGERY","CYCLES_ON_THERAPY","ORAL_CONTRACEPTION","PRIOR_TX_TO_IMPACT_SAMPLE","RADIATION_OTHER"
"ADJUVANT_CHEMO_REGIMEN","NUM_LINES_NTRK","NUMBER_OF_CYCLES_TRASTUZUMAB","DOSE_MG_DAY_STEROID_DURING_PD1","TX_SETTING","RADIATION_SITE"
"ADJUVANT_HORMONE_THERAPY","SURGERY_DATE_RELATIVE_TO_DX_MONTHS","NUMBER_OF_CYCLES_FLUORO-PYRIMIDINE","DOSE_MG_DAY_STEROID_PD1_START","HISTORY_NEOADJUVANT_TRTYN","PRD_RADIATION_SURGERY"
"PHARM_TX_MITOTANE_ADJUVANT","CALC_TREATMENT_NAIVE","TX_CYCLOPHOSPHAMIDE","DURATION_OF_THERAPY_DAYS","ADJUVANT","RADIATION_THERAPY_XRT_TYPE"
"RADADJUVANTRX","PREVIOUS_MAPKI","TX_CYTARABINE","DRUG_START","NEOADJUVANT","RADIATION_TYPE"
"RADIATION_TREATMENT_ADJUVANT","AGE_AT_RADIATION_START","DOSE_MG_DAY_STEROID_DURING_PD1","DURATION_OF_INDUCTION_TREATMENT","NEOADJ_CHEMOAGENT","RADIATION_TYPE_OTHER"
"AGENT","AGE_AT_RADIATION_STOP","DOSE_MG_DAY_STEROID_PD1_START","DURATION_OF_THERAPY_WEEKS","PRIOR_ADJUVANT_CHEMO","UV_RATE"
"CHEMOTHERAPY_AGENTS","CRDB_PRIOR_RX","DOSAGE","MOST_RECENT_TREATMENT_DURATION","ADJUVANT_CHEMO","PRD_SURGERY"
"ALPELISIB_DOSE","PATIENT_TO_UNDERGO_SURGERY","DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)","DOT_MONTHS","NEOADJ_CHEMO","SURGICAL_APPROACH_AT_DIAGNOSIS"
"ALPELISIB_SCHEDULING","NGS_PRIOR_THERAPY","COMPLETED_RADIATION_DOSE","TOTAL_TIME_PERIOD_MONTHS","NEOADJUVANT_CHEMO","PRD_OTHER_THERAPY"
"INTERFERON_ALPHA","ADC_THERAPY","DOSE_OF_RE-IRRADIATION","MONTHS_ON_TREATMENT","NEOADJ_CHEMOCYCLES","ALTERNATE_THERAPY_OTHER"
"ANDROGEN_DEPRIVATION_THERAPY","IO_THERAPY","RADIATION_DOSE_PELVIC_NODES_PRIMARY_TUMOR.","CUMULATIVE_TREATMENT_REGIMENS","ADJUVANT_CHEMO_REGIMEN","TIMING_OTHER_NOTES"
"TX_BORTEZOMIB","TKI_TREATMENT","RADIATION_DOSE","TREATMENT_SCHEDULE","ADJUVANT_CHEMOTHERAPY","PRD_PROSTATECTOMY"
"TX_CABOZANTINIB (XL-148)","TMZ_TREATMENT","RADIATION_THERAPY_DOSE_PARAAORTIC_NODES","ANY_THERAPY_2YRS","NEOADJUVANT_CHEMOTHERAPY","METASTASECTOMY_SITE"
"CARBOPLATIN_TX","TREATED_WITH_ICI","COMPLETED_TOTAL_RADIATION_DOSE","TERT_ANTIMETABOLITE_TX","ADJUVANT_CYCLES_NUM","PRD_TREATED_AT_ENROLLMENT"
"PD1_INHIBITOR_WITH_CELECOXIB","TERT_IO_TX","DOSE_REDUCTION","TIMING_OTHER_NOTES","TOTAL_CYCLES_NUM_NEOADJUVANT_ADJUVANT","TREATMENT_DETAIL_BEFORE_PDX"
"CHEMO_OTHER","PRIOR_TX_TO_IMPACT_SAMPLE","RT_TX_TOTAL_DOSE_TO_PELVIS","TREATMENT_CHANGED","ADJUVANT_HORMONE_THERAPY","TREATMENT_DETAILS"
"FIRSTLINE_CHEMO_GROUP","IO_TX","TX_ERIBULIN","TREATMENT_DETAIL_BEFORE_PDX","ADJUVANT_IMMUNOTHERAPY","PRIOR_TREATMENT"
"PRIOR_INTRAVESICAL_CHEMOTHERAPY","DX_TYPE","RADIOTHERAPY_FRACTIONS","TREATMENT_DETAILS","NEOADJUVANT_IMMUNOTHERAPY","CUMULATIVE_TREATMENT_STAGES"
"CHEMO_FIRST_LINE","NEOADJ_CHEMOAGENT","NUM_LINES_HORMONE","WEEKS_ON_TREATMENT","HISTORY_NEOADJUVANT_MEDICATION","TREATMENT_AT_MSK"
"CHEMO_REGIMEN_CATEGORY","PRIOR_ADJUVANT_CHEMO","NUM_LINES_IMMUNO",NA,"PHARM_TX_MITOTANE_ADJUVANT","TREATMENT_GROUP"
"CHEMOTHERAPY","NEOADJ_CHEMO","NUMBER_OF_PD1_INHIBITOR_INJECTIONS",NA,"PHARMACEUTICAL_TX_ADJUVANT","IMMUNE_TREATMENT"
"CHEMO_CONCURRENT_TYPE","NEOADJUVANT_CHEMO","NUM_LINES_IODINE",NA,"RADADJUVANTRX","CUMULATIVE_TREATMENT_TYPE_COUNT"
"CHEMO_CONCURRENT_TYPE_OTHER","NEOADJ_CHEMOCYCLES","TX_LAPATINIB",NA,"ADJUVANT_RADIATION_THERAPY","ALL_TX_AT_MSK"
"TERT_CISPLATIN_TX","ADJUVANT_CHEMO_REGIMEN","PRIOR_LINES",NA,"RADIATION_TREATMENT_ADJUVANT","RT_TX_REASON_NOT_COMPLETED"
"TX_CISPLATIN","ADJUVANT_CHEMOTHERAPY","NUM_LINES",NA,"HISTORY_NEOADJUVANT_STEROID_TX","RT_TX_REASON_NOT_COMPLETED_OTHER"
"CISPLATIN_TX","NEOADJUVANT_CHEMOTHERAPY","NUM_LINES_TARGETED",NA,"ADJUVANT_TARGETED","TX_LOCATION"
"PD1_INHIBITOR_CONCURRENTLY_WITH_HYDROXYUREA","ADJUVANT_HORMONE_THERAPY","PRIOR_LINES_OF_THERAPY",NA,"NEOADJUVANT_TARGETED",NA
"PD1_INHIBITOR_CONCURRENTLY_WITH_BEV","ADJUVANT_IMMUNOTHERAPY","NUMBER_OF_LINES_OF_TREATMENT_FOR_MET_DISEASE",NA,"ADJUVANT_THERAPY",NA
"PD1_INHIBITOR_CONCURRENTLY_WITH_DC_VAX","NEOADJUVANT_IMMUNOTHERAPY","LINES_OF_TX",NA,"NEOADJUVANT_THERAPY",NA
"PD1_INHIBITOR_CONCURRENTLY_WITH_NOVO-TTF","RADADJUVANTRX","LINES_OF_TX_PRIOR_IMPACT",NA,"NEOADJUVANT_TREATMENT_DETAILS",NA
"PD1_INHIBITOR_CONCURRENTLY_WITH_RE-IRRADIATION","ADJUVANT_RADIATION_THERAPY","PHARM_TX_MITOTANE_THERAPUTIC_LEVELS",NA,"ADJUVANT_TX",NA
"PD1_INHIBITOR_CONCURRENTLY_WITH_TEMODAR","RADIATION_TREATMENT_ADJUVANT","UV_RATE",NA,"HISTORY_NEOADJUVANT_TX_TYPE",NA
"NUMBER_OF_CYCLES_PLATINUM","HISTORY_NEOADJUVANT_STEROID_TX","CUMULATIVE_TREATMENT_REGIMEN_COUNT",NA,"ADJ_XRT",NA
"TMZ_CYCLES","ADJUVANT_TARGETED","CUMULATIVE_TREATMENT_REGIMENS",NA,"ADJUVANT_XRT",NA
"NUMBER_OF_CYCLES_PEMBROLIZUMAB","NEOADJUVANT_TARGETED","TX_RUXOLITINIB",NA,"NEOADJUVANT_XRT",NA
"NUMBER_OF_CYCLES_TRASTUZUMAB","NEOADJUVANT_TREATMENT_DETAILS","TX_SORAFENIB",NA,"CUMULATIVE_CHEMO",NA
"NUMBER_OF_CYCLES_FLUORO-PYRIMIDINE","ADJUVANT_TX","TUMOR_SURGERY_NUMBER",NA,"CHEMO_CONCURRENT_COURSE",NA
"TX_CYCLOPHOSPHAMIDE","HISTORY_NEOADJUVANT_TX_TYPE","SURGERY NUMBER",NA,"CHEMO_CONCURRENT_DOSE",NA
"TX_CYTARABINE","ADJ_XRT","TX_SVV-001",NA,"FIRSTLINE_CHEMO_GROUP",NA
"DOPAMINE","ADJUVANT_XRT","NUM_PRIOR_THERAPIES",NA,"CHEMO_CONCURRENT_FRACTIONS_TOTAL",NA
"DRUG_AND_DOSE_STEROID_DURING_PD1","NEOADJUVANT_XRT","PRIOR_SYSTEMIC_THERAPIES",NA,"PRIOR_INTRAVESICAL_CHEMOTHERAPY",NA
"DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)","ALKYLATING_AGENT","TX_TOPOTECAN",NA,"CHEMO_FIRST_LINE",NA
"DRUG","CHEMOTHERAPY_AGENTS","CUMULATIVE_TREATMENT_STAGE_COUNT",NA,"ANY_LINE_CHEMO",NA
"PD1_INHIBITOR_DRUG","ANDROGEN_DEPRIVATION_THERAPY","TREATMENT_GROUP",NA,"CHEMO_REGIMEN_CATEGORY",NA
"EPINEPHRINE","PD1_INHIBITOR_WITH_CELECOXIB","CUMULATIVE_TREATMENT_TYPE_COUNT",NA,"CONCURRENT_CHEMOTHERAPY",NA
"TX_ERIBULIN","CUMULATIVE_CHEMO","TX_TRISENOX(ATO)",NA,"POST_SAMPLE_CHEMOTHERAPY",NA
"ANTI_O_VIVERRINI_IGG","CHEMO_OTHER","TX_17-DMAG",NA,"PRE_SAMPLE_CHEMOTHERAPY",NA
"FORMULATION","R_CHOP_LIKE_CHEMO","TX_19D12",NA,"CHEMO_CONCURRENT_TYPE",NA
"PD1_INHIBITOR_WITH_IMATINIB","SYSTEMIC_CHEMO","TX_ABT-199",NA,"CHEMO_CONCURRENT_TYPE_OTHER",NA
"HISTORY_IMMUNOSUPPRESIVE_DX","CHEMO_CONCURRENT_COURSE","TX_ABT-263",NA,"TERT_CISPLATIN_TX",NA
"IMMUNOSUPPRESSION","CHEMO_OTHER_CYCLES","TX_ACTINOMYCIN D",NA,"HISTORY_HORMONAL_CONTRACEPTIVES_USE",NA
"HISTORY_IMMUNOSUPPRESSIVE_TX_OTHER","CHEMO_CYCLES","TX_APLIDIN",NA,"TX_INDUCTION_COURSES_INDICATOR",NA
"INDUCTION","CHEMO_CONCURRENT_DOSE","TX_AZD-2171",NA,"TX_MAINTENANCE_COURSES_INDICATOR",NA
"PD1_INHIBITOR","FIRSTLINE_CHEMO_GROUP","TX_AZD-6244",NA,"CURRENT_CYCLE",NA
"ANY_LINE_IODINE","CHEMO_CONCURRENT_FRACTIONS_TOTAL","TX_AZD1480",NA,"DOSE_MG_DAY_STEROID_DURING_PD1",NA
"NUM_LINES_IODINE","CHEMOTHERAPY+IMMUNOTHERAPY","TX_AZD8055",NA,"DOSE_MG_DAY_STEROID_PD1_START",NA
"TX_LAPATINIB","PRIOR_INTRAVESICAL_CHEMOTHERAPY","TX_BAL101553",NA,"TX_90DAYS_POST_RESECTION",NA
"DETAILS_FIRST_LINE_COMMENTS","CHEMO_FIRST_LINE","TX_BI6727 (VOLASERTIB)",NA,"DRUG_AND_DOSE_STEROID_DURING_PD1",NA
"FIFTH_LINE","ANY_LINE_CHEMO","TX_BMN-673",NA,"COMPLETED_RADIATION_DOSE",NA
"FOURTH_LINE","NUM_LINES_CHEMO","TX_BMS-354825",NA,"DOSE_OF_RE-IRRADIATION",NA
"THIRD_LINE","RADIATION_OR_CHEMOTHERAPY","TX_BMS-754807",NA,"RADIATION_DOSE_PELVIC_NODES_PRIMARY_TUMOR.",NA
"FIRST_LINE_THERAPY","CHEMO_REGIMEN_CATEGORY","TX_CBL0137",NA,"RADIATION_THERAPY_DOSE_PARAAORTIC_NODES",NA
"FIRST_LINE_TREATMENT","PRD_CHEMOTHERAPY","TX_CDX-011 (GLEMBATUMUMAB)",NA,"COMPLETED_TOTAL_RADIATION_DOSE",NA
"FIRST_LINE_MET_TX","CONCURRENT_CHEMOTHERAPY","TX_CGC(PG)-11047",NA,"DOSE_REDUCTION",NA
"MEDICATION","POST_SAMPLE_CHEMOTHERAPY","TX_CLORETAZINE",NA,"RT_TX_TOTAL_DOSE_TO_PELVIS",NA
"METHOXYTYRAMINE","PRE_SAMPLE_CHEMOTHERAPY","TX_CPX351",NA,"DURATION_OF_INDUCTION_TREATMENT",NA
"PHARM_TX_MITOTANE_THERAPUTIC_AT_PROG","ALKYLATING_CHEMOTHERAPY","TX_CX-5461 (POL1)",NA,"MOST_RECENT_TREATMENT_DURATION",NA
"PHARM_TX_MITOTANE_THERAPUTIC_AT_REC","CHEMOTHERAPY","TX_E7438/EPZ6438",NA,"STREOIDS_DURING_PD1_INHIBITOR",NA
"PHARM_TX_MITOTANE_THERAPUTIC_MACRO","PRIOR_TREATMENT_OF_CYTOTOXIC_CHEMOTHERAPY","TX_EC1456",NA,"HISTORY_IONIZING_RT_TO_HEAD",NA
"PHARM_TX_MITOTANE_THERAPUTIC_LEVELS","TREATMENT_CHEMOTHERAPY","TX_FENRETINIDE",NA,"ANY_LINE_HORMONE",NA
"PHARM_TX_MITOTANE_FOR_MACRO_DISEASE","CHEMOTHERAPY_TYPE","TX_GENZ-644282",NA,"HISTORY_MENOPAUSAL_HORMONE_THERAPY",NA
"PHARM_TX_MITOTANE_INDICATOR","CHEMO_TX","TX_GS-9820",NA,"HISTORY_IMMUNOSUPPRESIVE_DX",NA
"NOREPINEPHRINE","CHEMO_CONCURRENT_TYPE","TX_GSK690693",NA,"POST_SAMPLE_IMMUNOTHERAPY",NA
"TERT_OXALIPLATIN_TX","CHEMO_CONCURRENT_TYPE_OTHER","TX_GSK923295A",NA,"PRE_SAMPLE_IMMUNOTHERAPY",NA
"OXALIPLATIN_TX","PD1_INHIBITOR_CONCURRENTLY_WITH_HYDROXYUREA","TX_HGS-ETR1",NA,"HISTORY_IMMUNOSUPPRESSIVE_TX_OTHER",NA
"PREVIOUS_TREATMENT","PD1_INHIBITOR_CONCURRENTLY_WITH_BEV","TX_IMC-A12",NA,"INDUCTION",NA
"SURGERY_PROCEDURE","PD1_INHIBITOR_CONCURRENTLY_WITH_DC_VAX","TX_INK128-1110-028",NA,"TYPE_INDUCTION_TREATMENT",NA
"FIRST_SURGICAL_PROCEDURE_OTHER","PD1_INHIBITOR_CONCURRENTLY_WITH_NOVO-TTF","TX_JNJ26481585",NA,"TYPE_INDUCTION_TX",NA
"SURGICAL_PROCEDURE_FIRST","PD1_INHIBITOR_CONCURRENTLY_WITH_RE-IRRADIATION","TX_JNJ26854165",NA,"PD1_INHIBITOR_STARTED_FOR_PD",NA
"DEFINITIVE_SURGICAL_PROCEDURE","PD1_INHIBITOR_CONCURRENTLY_WITH_TEMODAR","TX_KPT-330",NA,"STEROIDS_WHEN_STARTED_PD1_INHIBITOR",NA
"PROCEDURE_TYPE","HISTORY_HORMONAL_CONTRACEPTIVES_USE","TX_LENOLIDAMIDE",NA,"DETAILS_FIRST_LINE_COMMENTS",NA
"PROTOCOL_AND_TREATMENT_ARM","ORAL_CONTRACEPTION","TX_LY 2606368",NA,"FIFTH_LINE",NA
"RADIATION_OTHER","DOSE_MG_DAY_STEROID_DURING_PD1","TX_MK-2206",NA,"FOURTH_LINE",NA
"CURRENT_REGIMEN","DOSE_MG_DAY_STEROID_PD1_START","TX_MK-8242",NA,"THIRD_LINE",NA
"CUMULATIVE_TREATMENT_REGIMENS","DRUG_AND_DOSE_STEROID_DURING_PD1","TX_MLN4924",NA,"ANY_LINE_TARGETED",NA
"TX_RUXOLITINIB","DOSE_OF_PEMBROLIZUMAB_PER_INJECTION (MG/KG)","TX_MLN8237",NA,"FIRST_LINE_THERAPY",NA
"INITIAL_RX","COMPLETED_RADIATION_DOSE","TX_MM-141",NA,"FIRST_LINE_TREATMENT",NA
"SUBSEQUENT_RX","DOSE_OF_RE-IRRADIATION","TX_NSC060043",NA,"FIRST_LINE_MET_TX",NA
"SORAFENIB_TREATMENT","RADIATION_DOSE_PELVIC_NODES_PRIMARY_TUMOR.","TX_NSC750854",NA,"TX_LINE",NA
"TX_SORAFENIB","RADIATION_DOSE","TX_PCI-32765",NA,"PRIOR_LINES",NA
"SURGERY_AT_DX","RADIATION_THERAPY_DOSE_PARAAORTIC_NODES","TX_PF-03084014",NA,"PRIOR_LINES_OF_THERAPY",NA
"SURGERY_FOR_POSITIVE_MARGINS","COMPLETED_TOTAL_RADIATION_DOSE","TX_PIXANTRONE",NA,"NUMBER_OF_LINES_OF_TREATMENT_FOR_MET_DISEASE",NA
"SURGERY_FOR_POSITIVE_MARGINS_OTHER","RT_TX_TOTAL_DOSE_TO_PELVIS","TX_PR-104",NA,"MAINTENANCE_TX",NA
"PRIMARY_SURGERY","PD1_INHIBITOR_DRUG","TX_RAPAMYCIN",NA,"PHARM_TX_MITOTANE_THERAPUTIC_AT_PROG",NA
"SURGERY","DRUG_TYPE","TX_RG7112",NA,"PHARM_TX_MITOTANE_THERAPUTIC_AT_REC",NA
"BREAST_SURGERY","STREOIDS_DURING_PD1_INHIBITOR","TX_RO4929097",NA,"PHARM_TX_MITOTANE_THERAPUTIC_MACRO",NA
"TYPE_OF_SURGERY","RADIOTHERAPY_FRACTIONS","TX_SAHA",NA,"PHARM_TX_MITOTANE_FOR_MACRO_DISEASE",NA
"SURGERY_TYPE","HISTORY_IONIZING_RT_TO_HEAD","TX_SAR3419",NA,"TREATMENT_NAIVE",NA
"TX_SVV-001","ANY_LINE_HORMONE","TX_SB-715992",NA,"TERT_OXALIPLATIN_TX",NA
"HISTORY_TAMOXIFEN_USE","NUM_LINES_HORMONE","TX_SCH 727965",NA,"TREATMENT_PALLIATIVE_RADIATION",NA
"ALTERNATE_THERAPY_OTHER","PRD_HORMONE_THERAPY","TX_SGI-1776",NA,"PREVIOUS_TREATMENT",NA
"THERAPY_PRIOR_TO_DERIVATION","HISTORY_MENOPAUSAL_HORMONE_THERAPY","TX_SGN-CD19A",NA,"FIRST_SURGICAL_PROCEDURE_OTHER",NA
"THERAPY","HORMONE_THERAPY","TX_STA9090 (GANETESPIB)",NA,"SURGICAL_PROCEDURE_FIRST",NA
"ENDOCRINE_THERAPY","TREATMENT_HORMONE_THERAPY","TX_STF-118804",NA,"PROTOCOL_AND_TREATMENT_ARM",NA
"BRACHYTHERAPY_TYPE","PD1_INHIBITOR_WITH_IMATINIB","TX_SU11248",NA,"PRD_OTHER_CANCER_RADIATION",NA
"BRACHYTHERAPY_TYPE_OTHER","HISTORY_IMMUNOSUPPRESIVE_DX","TX_TAK-701",NA,"PRIORRADIATIONFOROTHERCANCER",NA
"TIMING_OTHER_NOTES","IMMUNOSUPPRESSION","TX_TB-403",NA,"METASTATIC_RADIATION_THERAPY",NA
"PRD_PROSTATECTOMY","ANY_LINE_IMMUNO","TX_TL32711",NA,"PRIMARY_RADIATION_THERAPY",NA
"HEPATECTOMY","NUM_LINES_IMMUNO","TX_VS-4718",NA,"PRIOR_MALIGNANCY_RADIATION_TX",NA
"METASTASECTOMY","POST_SAMPLE_IMMUNOTHERAPY","TX_XL147",NA,"CURRENT_REGIMEN",NA
"METASTASECTOMY_SITE","PRE_SAMPLE_IMMUNOTHERAPY","TX_XL765",NA,"CUMULATIVE_TREATMENT_REGIMEN_COUNT",NA
"TREATMENT_PROSTATECTOMY","IMMUNOTHERAPY","TX_VINCRISTINE",NA,"CUMULATIVE_TREATMENT_REGIMENS",NA
"HYSTERECTOMY_TYPE","HISTORY_IMMUNOSUPPRESSIVE_TX_OTHER",NA,NA,"INITIAL_RX",NA
"OTHER_HYSTERECTOMY_TYPE","TYPE_INDUCTION_TREATMENT",NA,NA,"SUBSEQUENT_RX",NA
"TX_TOPOTECAN","TYPE_INDUCTION_TX",NA,NA,"SURGERY_ADVANCED_DISEASE",NA
"TREATMENT_DETAIL_BEFORE_PDX","KINASE_INHIBITOR",NA,NA,"TUMOR_SURGERY_NUMBER",NA
"TREATMENT_DETAILS","PD1_INHIBITOR_STARTED_FOR_PD",NA,NA,"SURGERY_AT_DX",NA
"PRIOR_TREATMENT","NUMBER_OF_PD1_INHIBITOR_INJECTIONS",NA,NA,"SURGERY_FOR_POSITIVE_MARGINS",NA
"PRETREATMENT_HISTORY","STEROIDS_WHEN_STARTED_PD1_INHIBITOR",NA,NA,"SURGERY_FOR_POSITIVE_MARGINS_OTHER",NA
"SYSTEMIC_TREATMENT","INTRAVESICAL_TREATMENT",NA,NA,"PRIMARY_SURGERY",NA
"2L_TREATMENT","ANY_LINE_TARGETED",NA,NA,"SURGERY_INDICATION",NA
"3L_TREATMENT","NUM_LINES_TARGETED",NA,NA,"SURGICAL_APPROACH_AT_DIAGNOSIS",NA
"TREATMENT","TREATMENT_PALLIATIVE_RADIATION",NA,NA,"TREATMENT_PRIOR_TO_SURGERY_INDICATOR",NA
"IMMUNE_TREATMENT","PREVIOUS_TREATMENT",NA,NA,"HISTORY_TAMOXIFEN_USE",NA
"TREATMENT_TYPE","PROCEDURE",NA,NA,"POST_SAMPLE_TARGETED",NA
"TX_TRISENOX(ATO)","SURGERY_PROCEDURE",NA,NA,"PRE_SAMPLE_TARGETED",NA
"TX_REG","FIRST_SURGICAL_PROCEDURE_OTHER",NA,NA,"TERT_TARGETED_TX",NA
"TERT_ANTHRACYCLINE_TX","SURGICAL_PROCEDURE_FIRST",NA,NA,"PRD_OTHER_THERAPY",NA
"TERT_CARBOLATIN_TX","DEFINITIVE_SURGICAL_PROCEDURE",NA,NA,"NUM_PRIOR_THERAPIES",NA
"TERT_PLATINUM_TX","PROCEDURE_TYPE",NA,NA,"PRIOR_SYSTEMIC_THERAPIES",NA
"TERT_TAXANE_TX","PRD_OTHER_CANCER_RADIATION",NA,NA,"ALTERNATE_THERAPY_OTHER",NA
"TERT_TOPO_I_INH_TX","PRD_RADIATION",NA,NA,"FIRST_THERAPY",NA
"TERT_TOPO_II_INH_TX","PRIORRADIATIONFOROTHERCANCER",NA,NA,"PRIOR_THERAPY",NA
"TX_17-DMAG","RADIATION",NA,NA,"ALTERNATE_THERAPY",NA
"TX_19D12","RADIATION_OTHER",NA,NA,"OTHER_CONCURRENT_THERAPY",NA
"TX_ABT-199","RADIATION_SITE",NA,NA,"SYSTEMIC_THERAPY",NA
"TX_ABT-263","PRD_RADIATION_SURGERY",NA,NA,"THERAPY_PRIOR_TO_DERIVATION",NA
"TX_ACTINOMYCIN D","METASTATIC_RADIATION_THERAPY",NA,NA,"PRD_TREATED_AT_ENROLLMENT",NA
"TX_APLIDIN","PRIMARY_RADIATION_THERAPY",NA,NA,"TREATMENT_CHANGED",NA
"TX_AZD-2171","RADIATION_THERAPY",NA,NA,"TREATMENT_DETAIL_BEFORE_PDX",NA
"TX_AZD-6244","RADIO_THERAPY",NA,NA,"CUMULATIVE_TREATMENT_STAGE_COUNT",NA
"TX_AZD1480","RADIOTHERAPY",NA,NA,"PRIOR_TREATMENT",NA
"TX_AZD8055","RADIOTHERAPY_TX",NA,NA,"TREATMENT_STATUS",NA
"TX_BAL101553","RADIATION_THERAPY_XRT_TYPE",NA,NA,"PRETREATMENT_HISTORY",NA
"TX_BI6727 (VOLASERTIB)","TREATMENT_RADIATION",NA,NA,"CUMULATIVE_TREATMENT_STAGES",NA
"TX_BMN-673","PRIOR_MALIGNANCY_RADIATION_TX",NA,NA,"CUMULATIVE_TREATMENT_TYPES",NA
"TX_BMS-354825","RADIATION_TYPE",NA,NA,"INITIAL_TREATMENT",NA
"TX_BMS-754807","RADIATION_TYPE_OTHER",NA,NA,"PRETREATED",NA
"TX_CBL0137","UV_RATE",NA,NA,"SYSTEMIC_TREATMENT",NA
"TX_CDX-011 (GLEMBATUMUMAB)","SALICYLATES",NA,NA,"2L_TREATMENT",NA
"TX_CGC(PG)-11047","STEROIDS",NA,NA,"3L_TREATMENT",NA
"TX_CLORETAZINE","SURGERY_ADVANCED_DISEASE",NA,NA,"HISTORY_REFLUX_DISEASE_TREATMENT",NA
"TX_CPX351","TUMOR_SURGERY_NUMBER",NA,NA,"OFF_TREATMENT",NA
"TX_CX-5461 (POL1)","PRD_SURGERY",NA,NA,"ON_TREATMENT",NA
"TX_E7438/EPZ6438","SURGERY_AT_DX",NA,NA,"ONGOING_TREATMENT",NA
"TX_EC1456","SURGERY_FOR_POSITIVE_MARGINS",NA,NA,"TREATMENT_AT_MSK",NA
"TX_FENRETINIDE","SURGERY_FOR_POSITIVE_MARGINS_OTHER",NA,NA,"TREATMENT_ONGOING",NA
"TX_GENZ-644282","PRIMARY_SURGERY",NA,NA,"TREATMENT_PRIOR_TO_RESECTION",NA
"TX_GS-9820","SURGERY_INDICATION",NA,NA,"IMMUNE_TREATMENT",NA
"TX_GSK690693","SURGERY NUMBER",NA,NA,"CUMULATIVE_TREATMENT_TYPE_COUNT",NA
"TX_GSK923295A","SURGERY",NA,NA,"MOST_RECENT_TREATMENT_TYPE",NA
"TX_HGS-ETR1","BREAST_SURGERY",NA,NA,"TX_BET_PRI_MET_SAMPLE_COLLECTION",NA
"TX_IMC-A12","HAD_SURGERY",NA,NA,"ALL_TX_AT_MSK",NA
"TX_INK128-1110-028","SURGICAL_APPROACH_AT_DIAGNOSIS",NA,NA,"OTHER_CYTOTOXIC_TX",NA
"TX_JNJ26481585","TREATMENT_PRIOR_TO_SURGERY_INDICATOR",NA,NA,"TERT_ALKYLATING_TX",NA
"TX_JNJ26854165","TYPE_OF_SURGERY",NA,NA,"TERT_ANTHRACYCLINE_TX",NA
"TX_KPT-330","SURGERY_TYPE",NA,NA,"TERT_CARBOLATIN_TX",NA
"TX_LENOLIDAMIDE","POST_SAMPLE_TARGETED",NA,NA,"TERT_CYTOTOXIC_TX",NA
"TX_LY 2606368","PRE_SAMPLE_TARGETED",NA,NA,"TERT_MICROTUBULE_TX",NA
"TX_MK-2206","TARGETED_MOLECULAR_THERAPY",NA,NA,"TERT_OTHER_CYTOTOXIC_TX",NA
"TX_MK-8242","TARGET_THERAPY",NA,NA,"TERT_PLATINUM_TX",NA
"TX_MLN4924","TARGETED_THERAPY",NA,NA,"TERT_TAXANE_TX",NA
"TX_MLN8237","TERT_TARGETED_TX",NA,NA,"TERT_TOPO_I_INH_TX",NA
"TX_MM-141","TARGETED_TX",NA,NA,"TERT_TOPO_II_INH_TX",NA
"TX_NSC060043","RECEIVED_TARGETED_TX",NA,NA,"POST_SAMPLE_TX",NA
"TX_NSC750854","PRIOR_SYSTEMIC_THERAPIES",NA,NA,"POSTOPERATIVE_TX",NA
"TX_PCI-32765","ALTERNATE_THERAPY_OTHER",NA,NA,"PRE_SAMPLE_TX",NA
"TX_PF-03084014","FIRST_THERAPY",NA,NA,"RT_TX_REASON_NOT_COMPLETED",NA
"TX_PIXANTRONE","ALTERNATE_THERAPY",NA,NA,"RT_TX_REASON_NOT_COMPLETED_OTHER",NA
"TX_PR-104","SYSTEMIC_THERAPY",NA,NA,"TX_LOCATION",NA
"TX_RAPAMYCIN","THERAPY",NA,NA,"POST_SAMPLE_XRT",NA
"TX_RG7112","ENDOCRINE_THERAPY",NA,NA,"PRE_SAMPLE_XRT",NA
"TX_RO4929097","THERAPIES",NA,NA,NA,NA
"TX_SAHA","BRACHYTHERAPY_TYPE",NA,NA,NA,NA
"TX_SAR3419","BRACHYTHERAPY_TYPE_OTHER",NA,NA,NA,NA
"TX_SB-715992","TERT_ANTIMETABOLITE_TX",NA,NA,NA,NA
"TX_SCH 727965","ANTIMETABOLITE_TX",NA,NA,NA,NA
"TX_SGI-1776","PRD_PROSTATECTOMY",NA,NA,NA,NA
"TX_SGN-CD19A","HEPATECTOMY",NA,NA,NA,NA
"TX_STA9090 (GANETESPIB)","METASTASECTOMY",NA,NA,NA,NA
"TX_STF-118804","METASTASECTOMY_SITE",NA,NA,NA,NA
"TX_SU11248","TREATMENT_PROSTATECTOMY",NA,NA,NA,NA
"TX_TAK-701","HYSTERECTOMY_TYPE",NA,NA,NA,NA
"TX_TB-403","OTHER_HYSTERECTOMY_TYPE",NA,NA,NA,NA
"TX_TL32711","TREATMENT_DETAIL_BEFORE_PDX",NA,NA,NA,NA
"TX_VS-4718","TREATMENT_DETAILS",NA,NA,NA,NA
"TX_XL147","PRIOR_TREATMENT",NA,NA,NA,NA
"TX_XL765","CUMULATIVE_TREATMENT_TYPES",NA,NA,NA,NA
"ANTHRACYCLINE_TX","INITIAL_TREATMENT",NA,NA,NA,NA
"PLATINUM_TX","HISTORY_REFLUX_DISEASE_TREATMENT",NA,NA,NA,NA
"TAXANE_TX","TREATMENT_PRIOR_TO_RESECTION",NA,NA,NA,NA
"TOPO_I_TX","TREATMENT",NA,NA,NA,NA
"TOPO_II_TX","IMMUNE_TREATMENT",NA,NA,NA,NA
"TX_VINCRISTINE","CYTOTOXIC_TREATMENT",NA,NA,NA,NA
"TRANSPLANT_TYPE","TREATMENT_CATEGORY",NA,NA,NA,NA
NA,"MOST_RECENT_TREATMENT_TYPE",NA,NA,NA,NA
NA,"TREATMENT_TYPE",NA,NA,NA,NA
NA,"TX_BET_PRI_MET_SAMPLE_COLLECTION",NA,NA,NA,NA
NA,"OTHER_CYTOTOXIC_TX",NA,NA,NA,NA
NA,"TERT_ALKYLATING_TX",NA,NA,NA,NA
NA,"TERT_CYTOTOXIC_TX",NA,NA,NA,NA
NA,"TERT_MICROTUBULE_TX",NA,NA,NA,NA
NA,"TERT_OTHER_CYTOTOXIC_TX",NA,NA,NA,NA
NA,"POSTOPERATIVE_TX",NA,NA,NA,NA
NA,"ALKYLATING_TX",NA,NA,NA,NA
NA,"CYTOTOXIC_TX",NA,NA,NA,NA
NA,"MICROTUBULE_TX",NA,NA,NA,NA
NA,"NUCLEOSIDE_TX",NA,NA,NA,NA
NA,"XRT_TX",NA,NA,NA,NA
NA,"TRANSPLANT_TYPE",NA,NA,NA,NA
NA,"POST_SAMPLE_XRT",NA,NA,NA,NA
NA,"PRE_SAMPLE_XRT",NA,NA,NA,NA
